P4ADNow is a bipartisan patient advocacy organization fighting for lower drug prices. We mobilize patients in support of legislation to fix our broken system.
Washington, DC
Joined December 2017
- Tweets3.4K
- Following1.1K
- Followers2.3K
- Likes1.3K
Patients For Affordable Drugs NOW retweeted
Big news! Our US v. Pharma: Fighting to Protect Medicare Negotiation campaign has been named a finalist for the Anthem Awards!
Medicare drug price negotiation is a historic step toward lowering prescription drug prices, but the policy can be complex and difficult to connect with audiences beyond Medicare beneficiaries. That’s why we partnered with digital creators to bring this issue to life through authentic storytelling and make it more accessible and relevant to younger and more diverse audiences.
Selected from more than 2,500 projects, we’re proud to see this work recognized alongside other campaigns driving social impact. Now, we need your help!
Vote for P4AD for the Anthem Community Voice Award and help us celebrate this work: celebrate.anthemawards.com/P…
Voting is open through October 29. Don’t forget to verify your email after voting to make sure your vote counts!
Thank you for helping us keep up the fight for lower prescription drug prices! #AnthemAwards @anthemawards
Patients For Affordable Drugs NOW retweeted
Big Pharma is fighting to stop lower costs for patients, but the drug pricing lawsuits aren't going their way.
@MerithBasey @P4AD_ @P4ADNow discusses with @lpackard on the full ep of #CareTalk: youtube.com/live/LdlNGhlThu8
Patients For Affordable Drugs NOW retweeted
Pharma patent abuse is getting the national attention it deserves. @EpochTimes just published a deep dive on how drug companies stack overlapping patents to keep prices high - featuring P4AD advocates living with the consequences every day.
Read it here: lnkd.in/eEx5RdFu
Patients For Affordable Drugs NOW retweeted
One in three Americans struggles with high medication costs due to the pharmaceutical industry's practices.
Learn more from @MerithBasey @P4AD_ youtube.com/watch?v=L6xAoVV4…
Patients For Affordable Drugs NOW retweeted
It's time we rein in Big Pharma's abuse of the patent system.
That’s why my colleagues should join my bill with @SenAmyKlobuchar and @SenHawleyPress so we can get more affordable generics on the market and save patients money at the pharmacy counter.
NEW VIDEO: We just released a new video explaining one of the most important — and least talked about — drivers of high drug prices: patent abuse. The ETHIC Act would close the loopholes drug companies exploit to block cheaper generics. Watch, share, and urge Congress to act: tinyurl.com/e3kr3vv2
Patients For Affordable Drugs NOW retweeted
We will continue to fight for the world that David dreamed of, a world where lifesaving medicines can be within reach of every patient. Rest in power, David.
A statement from Chuck Hurley, Board Chair of Patients For Affordable Drugs and David’s close friend of more than 40 years, honoring David’s life and legacy following his passing on Friday.
patientsforaffordabledrugs.o…
Patients For Affordable Drugs NOW retweeted
Saddened to learn of the passing of David Mitchell, founder of @P4AD_, in his 15-year battle with multiple myeloma cancer. A tireless advocate for reining in Big Pharma monopoly prices, I frequently consulted him.
David, who relied on constant innovation to treat his ever-evolving cancer, recognized that American taxpayers are the true angel investors in innovation.
His leadership will be sorely missed as we continue the struggle to deliver new, affordable treatments and cures.
Patients For Affordable Drugs NOW retweeted
.@jonstewart and @linamkhan discuss how pharma companies build patent thickets.
Patients For Affordable Drugs NOW retweeted
P4AD's Merith Basey @GlobalDiaBEATes and Michael Lieberman @Footnote24 joined McGill to discuss pharma's legal crusade to end drug price negotiations, and how we're fighting back — listen below!
open.spotify.com/episode/6Lp…
Patients For Affordable Drugs NOW retweeted
“Expediting the biosimilar approval process – by cutting unnecessary red tape and streamlining duplicative clinical trials – will help speed lower-cost treatments … delivering relief to patients” more from @P4ADNOW on recent @FDA action: patientsforaffordabledrugsno…
Patients For Affordable Drugs NOW retweeted
NEW: "Tariffs would disrupt international supply chains, forcing companies to decide whether to pass on increased costs to patients and exacerbate existing drug shortages"
thehill.com/homenews/adminis…
Patients For Affordable Drugs NOW retweeted
New reporting from Bloomberg Law's @nyahphengsitthy on the Orphan Cures Act: "Drug pricing experts have gone as far to say the exemption walks back Trump’s agenda to lower US drug prices" — "it carves out more and more from negotiations"
news.bloomberglaw.com/health…
Patients For Affordable Drugs NOW retweeted
We agree PBMs drive up costs. But that's not the whole story. Drug companies abuse the patent system to block generics & biosimilars- often filing 100+ patents on one drug- keeping prices high for patients. We need to fix both to truly lower drug prices. patientspushforcompetition.o…
Blaming patents for high drug prices is a convenient distraction. The real anti-competitive force? PBMs -- opaque middlemen that restrict access and distort costs. As the @FTC and @TheJusticeDept heard last week, they’re the ones distorting competition.
Patients For Affordable Drugs NOW retweeted
The June 25 edition of @LatNewsletter is an opinion piece by Sonia Vega, a mother and wife from Phoenix, Arizona. Even with a full-time job and health insurance, she still can't afford her diabetes medication due to its high cost.
thelatinonewsletter.org/p/la…
Patients For Affordable Drugs NOW retweeted
“I go to pick up my Rybelsus and it’s $425”
Novo Nordisk, the drug company behind the popular GLP-1 drug Rybelsus, is gaming the patent system to monopolize the semaglutide market.
The company’s abusive patenting schemes generate billions in revenue, much of which is used to boost its stock price and enrich its shareholders.
Patients For Affordable Drugs NOW retweeted
Eliquis is a blood thinner that is marketed by Bristol Myers Squibb. It carries a list price of over $7,000 per year.
We investigated the patenting strategies around Eliquis. Here's what we found:
📄43 patent applications have been filed
📄22 patents have been granted
These granted patents provide 34.1 years of patent protection, approximately 1.75X the 20-year limit intended by the U.S. patent system.
In Europe, Bristol Myers Squibb’s market monopoly on Eliquis ended in 2022. In the U.S., thanks to additional patents, Bristol Myers Squibb is expected to extend its market monopoly until at least 2028—over 8 years after Eliquis’s primary patent expired and over 6 years later than Europe.
Patients For Affordable Drugs NOW retweeted
Eli Lilly spent more on R&D during the period but is now shifting its business strategy to cater more to shareholders. The company spent $2.5B on buybacks last year and increased its quarterly dividend by 15%. Last December, it also announced a new $15B buyback program.
Patients For Affordable Drugs NOW retweeted
Between 2020-2024, Novo Nordisk spent 41% more on shareholder enrichment (buybacks and dividends) than it did on R&D.
Patients For Affordable Drugs NOW retweeted
I just wrote a letter with @P4ADNOW: Tell Your Representative: Stop the ORPHAN Cures Act!
Write one here: actionnetwork.org/letters/c9…
Patients For Affordable Drugs NOW retweeted
I just wrote a letter with @P4ADNOW: Tell Your Representative: Stop the ORPHAN Cures Act!
Write one here: actionnetwork.org/letters/c9…
